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Biotransformation of clovane derivatives. Whole cell fungi mediated domino
synthesis of rumphellclovane A†
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Here we describe the biotransformation of clovane derivatives by filamentary fungi Pestalotiopsis
palustris and Penicillium minioluteum, and the application of the latter to the synthesis and determination
of the absolute configuration of rumphellclovane A (2). Methoxyclovanol (1), a growth inhibitor of the
phytopathogen Botrytis cinerea, is metabolised by P. palustris to yield rumphellclovane A (2), a natural
compound recently isolated from the gorgonian coral Rumphella antipathies, two new compounds,
(1R,2S,5S,8R,9S,10R)-2-methoxyclovane-9,10-diol (5) and (1S,2S,5S,7R,8R,9R)-2-methoxyclovane-7,9-
diol (6), hydroxylated in positions not easily accessed by classic synthetic chemistry, and clovanodiols 3
and 4. P. minioluteum is able to selectively transform methoxyclovanol (1) into clovanodiols 3 and 4 and,
in turn, lactone 8, the putative intermediate in the above mentioned synthesis of rumphellclovane A (2),
into compound 2 via a domino process. The ability of P. minioluteum to carry out the cleavage of ethers
on clovane derivatives is also evaluated.
Introduction
Clovane derivatives are a group of terpenes which have dis-
played interesting biological activities.1 Compounds with a
clovane skeleton have exhibited activity as growth inhibitors of
the fungus Botrytis cinerea, a serious plant pathogen that has
developed resistance to some commercial fungicides.2 The bio-
transformation and detoxification of some bioactive clovanes by
B. cinerea has already been studied.3 These studies have revealed
that the cleavage of ether function at C-2 of the clovane skeleton
and redox reactions at C-9, are key detoxification reactions
carried out by the fungus. These results suggest that active
clovane derivatives can be considered as a new class of non per-
sistent fungistatic compounds.1a,3
An approach to the development of this class of fungistatic
agents against B. cinerea requires the evaluation of a number of
clovane skeleton derivatives featuring different oxidation pat-
terns to those shown on clovanes metabolised by B. cinerea,4
irrespective of cleaving or not cleaving an ether function at the
C-2 position. Here, the use of other microorganisms as biotrans-
formation agents can be a useful methodology insofar as these
can give rise to products oxidised at positions not easily accessed
by classic synthetic chemistry, with the added advantage of mild
reaction conditions.5
The cleavage of a C–O bond of the ether functional group is a
well known reaction in organic synthesis and many methods
have been developed.6 However, these methods entail disadvan-
tages such as the utilization of harsh conditions, use of toxic,
expensive, and unstable reagents or catalysts and the formation
of mixtures and low product yield. Microbiological methods,
potentially milder and more economical, have typically been
applied to the breakdown of agro-chemicals and raw materials
like lignin,7 and only recently there are reports of preparative
applications for the cleavage of ether groups,8 even selectively.9
The microorganisms responsible for ether cleavage can poten-
tially be useful as tools in synthetic methodology such as the
transformation of methoxy into hydroxy functional groups.
This paper describes the biotransformation of
(1S,2S,5S,8R,9R)-2-methoxyclovan-9-ol (1) by the fungi Pesta-
lotiopsis palustris and Penicillium minioluteum, evaluates the
ability of the latter to carry out the cleavage of ethers on clovane
derivatives and describes its application to the synthesis and
determination of the absolute configuration of rumphellclovane
A (2), a novel clovane-related derivative isolated from the gorgo-
nian coral Rumphella antipathies.10
Results and discussion
(1S,2S,5S,8R,9R)-2-Methoxyclovan-9-ol (1), prepared from
(–)-caryophyllene oxide,11 was used as the substrate for
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biotransformations with P. palustris and P. minioluteum. The
incubation of 1 by P. palustris under surface culture conditions
gave rise to compounds 2 (2%), 3 (3%), 4 (10%), 5 (1%) and 6
(4%)5 after ten days (Scheme 1). Analysis of the spectroscopic
data of compound 2 showed that this compound was identical to
rumphellclovane A,10 a plausible clovane derivative, recently
isolated from the gorgonian coral Rumphella antipathies and
whose common biosynthetic origin was proposed. Rumphell-
clovane A (2) has a rearranged lactone skeleton probably formed
as a result of a four-part, domino-process reaction: demethylation
of the methoxyl group at C-2, oxidation of the hydroxy group at
C-9, Baeyer–Villiger oxidation at the C-8/C-9 bond and further
translactonization (Scheme 2).
Compounds 3 and 4, identified by analysis of their spectro-
scopic data respectively as (1S,2S,5S,8R,9R)-clovane-2,9-diol
(3)12 and (1S,2S,5S,8R,9S)-clovane-2,9-diol (4),3c resulted from
the demethylation of the starting material at position C-2 (com-
pound 3), while further epimerization at C-9 led to compound 4.
Two additional metabolites, 5 (1.0 mg, 1%) and 6 (4.8 mg,
4.8%), were obtained from the biotransformation of methoxyclo-
vanol (1) by P. palustris. The 13C NMR spectra of these novel
compounds showed 16 carbons, four methyl (one methoxyl),
five methylene, four methyne and three quaternary carbons, and
their HREIMS gave ion peaks consistent with the formula
C16H28O3.
The structures of compounds 5 and 6 were determined using a
combination of 1D and 2D NMR spectroscopy (Table 1, Fig. 1).
Comparison of δC from incubated compound 1 and compound 5,
pointed to multiplicity as well as chemical changes in resonance
for C-10 from δC 26.0 (t) in compound 1
11 to δC 68.0 (d) in com-
pound 5. The presence of a hydroxy group at this position was
confirmed by COSY correlations of signal at δH 3.94 (H-10)
with those at δH 1.35 (H-11β), δH 1.54 (H-11α) and δH 3.21
Scheme 2
Scheme 1
Table 1 1H and 13C NMR data, (1R,2S,5S,8R,9S,10R)-2-meth-
oxyclovane-9,10-diol (5) and (1S,2S,5S,7R,8R,9R)-2-methoxyclovane-







Position δH (600 MHz)
δC




2 α: 3.38 dd
(5.6, 10.0)
90.9 α: 3.19 dd
(3.9, 5.4)
89.8
3 α: 1.71 dd
(5.6, 12.0)







5 β: 1.47 m 52.7 β: 1.84–1.86 m 50.8
6 a: 1.32–1.41 m 21.4 α: 1.95 ddd
(1.6, 7.6, 14.8)
31.7
b: 0.85–0.90 m β: 1.64 m





9 β: 3.21 d (3.4) 78.5 β: 3.88 brs 68.5
10 β: 3.94 ddd
(3.4, 5.4, 12.3)
68.0 α: 1.70–1.80 m 30.0
β: 2.02–2.15 m
11 α: 1.54 t (12.3) 36.7 a,b: 1.60–1.65 27.9
β: 1.35 m
12c a: 0.96 d (12.7) 36.6 a: 0.96 m 38.4
b: 1.59 d (12.7) b: 1.54 dd
(1.6, 13.3)
13α 0.87 s 25.7 0.98 s 27.2
14β 1.03 s 31.6 1.01 s 32.7
15 0.98 s 28.9 1.07 s 25.5
–OCH3 3.33 s 58.5 3.27 s 57.2
aCD3OD.
bCDCl3.
cGreek letters are used to indicate relative
stereochemistry; where no clear assignment of relative stereochemistry
can be made. Latin letters (a, b) are used to distinguish between
diastereotopic protons connected to the same carbon (same position).
Fig. 1 Selected NOESY correlations found for compounds 5 and 6.
















































(H-9β) and an HMBC correlation of C-10 with signals at δH
1.35 (H-11β) and δH 1.54 (H-11α). NOE effects among signals
δH 3.94 (H-10) and δH 1.18 (H-7β), δH 1.47 (H-5β) and δH 3.21
(H-9β) supported the assignment of CHOH at C-10 as H-10β
(Fig. 1) and confirmed the structure of this compound as
(1R,2S,5S,8R,9S,10R)-2-methoxyclovane-9,10-diol (5).
Comparison of δC of incubated compound 1 and compound 6,
pointed to multiplicity and chemical changes in resonance for C-7
from δC 33.1 (t) in compound 1
11 to δC 76.5 (d) in compound 6.
The presence of a hydroxy group at this position was confirmed
by COSY correlations of the signal at δH 3.69 (H-7) with those at
δH 1.64 (H-6β) and δH 1.94 (H-6α) and HMBC correlations of
C-7 with signals at δH 0.96 (H-12a), δH 1.07 (H3-15), δH 1.54
(H-12b), δH 1.64 (H-6β), and δH 1.94 (H-6α). NOE effects
among signals δH 3.69 (H-7) and δH 0.98 (H3-13α), δH 1.07
(H3-15) and δH 1.95 (H-6α) supported the assignment of CHOH
at C-7 as H-7α (Fig. 1) and confirmed the structure of this com-
pound as (1S,2S,5S,7R,8R,9R)-2-methoxyclovane-7,9-diol (6).
The incubation of compound 1 by P. minioluteum under
surface culture conditions for ten days led only to compounds 3
and 4. Interestingly, the transformation was more selective and
the yields were higher (3, 17% yield and 4, 11% yield) than
those observed for the biotransformation of compound 1 by
P. palustris.
In order to evaluate whether the C–O bond cleavage ability of
P. minioluteum can be extended to the other side chains other
than methyl, we prepared and incubated clovane derivatives 9,
10 and 11 with whole cell cultures of P. minioluteum. Com-
pounds 9 and 10, not previously described in the literature, were
prepared by TCNE catalysed solvolysis of (−)-caryophyllene
oxide with n-propanol and n-pentanol, respectively
(Scheme 3).11 Molecular formulas C18H32O2 and C20H36O2
were assigned to compounds 9 and 10 respectively as derived
from their HREIMS. Structural elucidation of compounds 9 and
10 was achieved by a combination of 1D and 2D NMR spec-
troscopy and confirmed the structure of these compounds as
(1S,2S,5S,8R,9R)-2-propoxyclovan-9-ol (9), (1S,2S,5S,8R, 9R)-
2-pentoxyclovan-9-ol (10). The compound (1S,2S,5S,8R, 9R)-2-
(2′-(p-nitrophenoxy)ethoxy)clovan-9-ol (11) was prepared as
reported in a previous publication.3a
In three independent experiments, 60 mg of compounds 9–11
were incubated with P. minioluteum in two Roux-type bottles for
10 days (Scheme 4), the extracts were studied by gas chromato-
graphy coupled to mass spectrometry, column chromatography
and HPLC and further spectroscopic characterization of the com-
pounds isolated was carried out. Biotransformation of propoxy-
clovanol 9 also produced clovanodiols 3 and 4 but at lower
yields than those observed in the biotransformation of compound
1 under comparable conditions (Table 2). In contrast, indepen-
dent biotransformation of compounds 10 and 11 with P. minio-
luteum did not yield any transformed clovane derivatives, only
leading to the recovery of starting material. Even though no
obvious solubility problems were observed, their higher lipophi-
licity could explain the lack of metabolism through mechanisms
observed for compounds 1 and 9. Interestingly, both compounds
present calculated13 log P values close to the upper limit of log
P14 established by the Lipinsky “rule of five” for oral availability
of drugs15 which provides a guide in the search for active prin-
ciples (compound 10, log P = 5.004; compound 11, log P =
4.824). On the other hand, log P for compounds 1 (log P =
3.061) and 9 (log P = 3.939), which are metabolised by the
fungus, fall well within the margins of the Lipinski rule for log
P. These results seem to indicate that the length and nature of the
side chain of the clovane skeleton at C-2 have a significant
influence on the ability of P. minioluteum to remove it; only sub-
strates with a small enough side chain as those presented in com-
pounds 1 and 9 seem to be metabolized by the fungi.
Since P. minioluteum was capable of interaction at the C-2 and
C-9 positions on compounds with clovane skeletons yielding
reasonable amounts of biotransformation product, we tested a
plausible application of this fungus as a biocatalyst to a biomi-
metic synthesis of rumphellclovane A (2).10 Compound 1 was
oxidized with PCC to give ketone 73c which, in turn, was trans-
formed by treatment with MCPBA to lactone 8 (67% yield), a
light yellow solid with molecular formula C16H26O3 as derived
from its HREIMS. IR spectrum of this compound suggested the
presence of a lactone group (1711, 1186 cm−1). The shift in C-8
resonance from δC 44.4 in compound 7 to δC 80.0 in compound
8 in its 13C NMR spectrum indicated that lactonisation was
accomplished with insertion of an oxygen atom between C-9
and C-8. Further analysis of 1D and 2D NMR spectroscopy
allowed us to confirm the structure of this compound as
(1S,2S,5S,8R)-8,9-seco-8-hydroxy-2-methoxyclovane-9-lactone




Table 2 Metabolites of clovanes by P. minioluteum
Substrates Metabolites (yield, %)
1 3 (17), 4 (11)
9a 3 (8), 4 (2)
10 —b
11 —b
a 7 mg of compound 9 were recovered. bNo metabolites were obtained.
















































Compound 8 was then incubated with a surface culture of
P. minioluteum for 10 days. As a result, a compound with identi-
cal spectroscopic and physical data to rumphellclovane A (2)
was obtained at a yield of 16% via a domino demethylation/
translactonization process. These results support the hypothetical
biosynthetic route proposed for compound 2.10 Anyway, either
compound 8 or 8a could be envisaged as intermediates in the
transformation of methoxyclovanol (1) to rumphellclovane A (2)
by P. palustris.
Additionally, the optical rotation of compound 2, obtained
through microbiological transformation (Schemes 1 and 5),
showed the same sign and magnitude to that described for the
marine natural product10 thus supporting the absolute configur-
ation for rumphellclovane A as 1S,2S,5S,8R.
Conclusion
(1S,2S,5S,8R,9R)-2-Methoxyclovan-9-ol (1) is metabolised by a
whole cell culture of P. palustris to yield rumphellclovane A (2),
a natural compound recently isolated from the gorgonian coral R.
antipathies, two new compounds, (1R,2S,5S,8R,9S,10R)-2-meth-
oxyclovane-9,10-diol (5) and (1S,2S,5S,7R,8R,9R)-2-methoxy-
clovane-7,9-diol (6), hydroxylated at positions not easily
accessed by classic synthetic chemistry, and the previously
described (1S,2S,5S,8R,9R)-clovane-2,9-diol (3) and
(1S,2S,5S,8R,9S)-clovane-2,9-diol (4).
We also evaluated the ability of the fungus P. minioluteum to
perform the cleavage of an ether function at C-2 on clovane
derivatives. Results show that the length and nature of the side
chain have a significant influence on the reaction. We also
applied the fungus P. minioluteum in a biomimetic synthesis of
rumphellclovane A (2), where the fungus was able to mediate
the demethylation/translactonization domino reactions which
transformed lactone 8 into the natural product. Finally, this syn-
thesis led to the assignment of the absolute configuration of rum-




Melting points were measured with a Reichert-Jung Kofler block
and are uncorrected. Optical rotations were determined with a
Perkin-Elmer 341 polarimeter. [α]D Values are given in 10
3
degree cm2 g−1, concentration of the sample in 102 cm−3 g. IR
spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR
spectrophotometer. 1H and 13C NMR measurements were
obtained on Varian INOVA 400 and INOVA 600 NMR spec-
trometers with SiMe4 as the internal reference. J values are given
in Hz. NMR assignments were made by a combination of 1D
and 2D techniques and by comparison with those made for pre-
viously described compounds, where appropriate. Mass spectra
were recorded on a Finnigan Voyager spectrometer at 70 eV.
High-resolution mass spectra were recorded on a Micromass
Autospec spectrometer at 70 eV. HPLC was performed with a
Hitachi/Merck L-6270 apparatus equipped with a UVVIS detec-
tor (L 4250) and a differential refractometer detector (RI-71).
TLC was performed on Merck Kiesegel 60 F254, 0.2 mm thick.
Silica gel (Merck) was used for column chromatography. Purifi-
cation by HPLC was accomplished using a Si gel column
(LiChrospher Si 60, 10 μm, 1 cm wide, 25 cm long).
Synthesis of the substrates
(1S,2S,5S,8R,9R)-2-Methoxyclovan-9-ol (1) (1S,2S,5S,8R)-2-
methoxyclovan-9-one (7) and (1S,2S,5S,8R,9R)-2-(2′-(p-nitro-
phenoxy)ethoxy)clovan-9-ol (11) were prepared according to
procedures described in the literature.3c,11
(1S,2S,5S,8R)-8,9-Seco-8-hydroxy-2-methoxyclovane-9-lactone
(8). 327 mg (1.31 mmol) of compound 7 were dissolved by stir-
ring in 40 mL of CH2Cl2 at room temperature. Then, 2645 mg
(15.33 mmol) of MCPBAwere added and the reaction monitored
by TLC. After 25 h the reaction mixture was neutralized with
Na2CO3, and extracted with ethyl acetate. The organic layer was
washed with a saturated solution of NaHCO3, dried over anhy-
drous Na2SO4, filtered and the solvent was evaporated under
reduced pressure. Column chromatography of the crude reaction
mixture on silica gel, eluted with a gradient mixture of petroleum
ether–EtOAc yielded compound 8 (233 mg, 0.87 mmol, 67%
yield). Obtained as a light yellow solid [α]25D −21.4 (c 0.1,
CH3OH); IR (film) νmax/cm
−1 1711, 1186 (lactone); δH
(400 MHz; CDCl3,) 0.87 (3H, s, H3-13α), 1.07 (3H, s, H3-14β),
1.09 (1H, m, H-6a), 1.39 (3H, s, H3-15), 1.42 (1H, m, H-11a),
1.45 (1H, t, J 11.5, H-3β), 1.59 (1H, m, H-6b), 1.55 (1H, m,
H-5β), 1.61 (1H, d, J 15.3, H-12a), 1.77 (1H, dd, J 5.6 and 11.5,
H-3α), 1.79 (1H, m, H-7a), 1.85 (1H, m, H-11b), 1.97 (1H, d, J
15.3, H-12b), 2.02 (1H, m, H-7b), 2.68–2.83 (2H, H-10a,b),
3.32 (3H, s, OCH3), 3.35 (1H, dd, J 5.6 and 11.5, H-2α); δC
(100 MHz, CDCl3) 20.3 (t, C-6), 25.5 (q, C-13), 30.8 (t, C-11),
31.0 (q, C-14), 32.2 (q, C-15), 32.8 (t, C-10), 35.5 (t, C-7), 36.8
(s, C-4), 43.8 (t, C-3), 44.8 (s, C-1), 46.9 (t, C-12), 51.0 (d,
C-5), 58.3 (q, –OCH3), 80.0 (s, C-8), 90.7 (d, C-2), 174.7 (s,
C-9); HMBC (selected correlations) C-8 → H-7a, H-7b, H-12a,
H-12b, H3-15; C-9 → H-10a, H-10b, H-11a, H-11b; C-12 →
H-2α, H3-15; EIMS m/z 266 (M
+, 2%), 251 (M+ − 15, 3), 248
(M+ − 18, 2), 210 (8), 164 (44), 161 (55), 119 (65), 105 (100),
99 (96); HREIMS m/z 266.1981 [M]+ (calcd for C16H26O3,
266.1882).
(1S,2S,5S,8R,9R)-2-Propoxyclovan-9-ol (9), (1S,2S,5S,8R,9R)-
2-pentoxyclovan-9-ol (10). 1 g (4.54 mmol) of
Scheme 5
















































(−)-caryophyllene oxide was dissolved by stirring in 20 mL of
either n-propanol or n-pentanol at room temperature. Then,
60 mg (0.47 mmol) of tetracyanoethylene (TCNE) were added
and the reaction was monitored by TLC. After 18 h the solvent
was evaporated under reduced pressure. Column chromatography
of the crude reaction mixture on silica gel, eluted with a gradient
mixture of petroleum ether–EtOAc, combined with HPLC purifi-
cation, yielded compound 9 (301 mg, 1.07 mmol, 24%) or
284 mg of compound 10 (284 mg 0.92 mmol, 20%).
(1S,2S,5S,8R,9R)-2-Propoxyclovan-9-ol (9). Obtained as white
crystals; mp 68–70 °C (from EtOAc); [α]25D +9.3 (c 0.38,
CHCl3); IR (film) νmax/cm
−1 3447 (OH),;δH (400 MHz, CDCl3)
0.85 (3H, s, H3-13α), 0.90 (3H, t, J 6.8, H3-3′), 0.95 (3H, s, H3-
15), 0.97 (1H, m, H-12a), 1.01 (3H, s, H3-14β), 1.09 (1H, m,
H-7a), 1.10 (1H, m, H-11a), 1.29 (1H, m, H-6a), 1.37 (1H, m,
H-7b), 1.39 (1H, m, H-5β), 1.39 (1H, m, H-6b), 1.49 (1H, dd, J
10.4 and 11.8, H-3β), 1.55 (2H, m, H-2′), 1.57 (1H, m, H-12b),
1.58 (1H, m, H-10α), 1.66 (1H, dd, J 6.0 and 11.8, H-3α), 1.69
(1H, m, H-11b), 1.97 (1H, dddd, J = 3.2; 4.8; 14.2; 14.3,
H-10β), 3.31 (1H, m, H-9β), 3.36 (1H, m, H-1′a), 3.39 (1H, dd,
J 6.0 and 10.4, H-2α), 3.42 (1H, m, H-1′b); δC (100 MHz,
CDCl3) 10.7 (q, C-3′), 20.6 (t, C-6), 23.4 (t, C-2′), 25.4 (q,
C-13α), 26.1 (t, C-10), 26.7 (t, C-11), 28.4 (q, C-15), 31.3 (q,
C-14β), 33.2 (t, C-7), 34.7 (s, C-8), 36.5 (t, C-12), 37.0 (s, C-4),
44.3 (s, C-1), 44.7 (t, C-3), 50.6 (d, C-5), 72.3 (t, C-1′), 75.3 (d,
C-9), 88.3 (d, C-2); HMBC (selected correlations) C-1 → H-2α;
C-2 → H-3α, H-3β, H-12a, H-12b; C-1′ → H2-2′, H3-3′; C-2′ →
H-1′a. H-1′b, H3-3′; C-3′ → H-2′, H-1′a. H-1′b; EIMS m/z 280
(M+, 16%), 265 (M+ − 15, 12), 220 (M+ − 60, 12), 205 (21),
187 (13), 161 (21), 127 (100), 105 (27), 85 (73); HREIMS m/z
280.2422 [M]+ (calcd for C18H32O2, 280.4455).
(1S,2S,5S,8R,9R)-2-Pentoxyclovan-9-ol (10). Obtained as
white crystals; mp 35–38 °C (from EtOAc); [α]25D +11.3 (c 0.36,
CHCl3); IR (film) νmax/cm
−1 3443 (OH); δH (400 MHz, CDCl3)
3.37 (1H, dd, J 5.6, 10.0, H-2α), 1.48 (1H, dd, J 10.0, 11.9,
H-3β), 1.66 (1H, dd, J 5.6, 11.9, H-3α), 1.38 (1H, m, H-5β),
1.28–1.42 (2H, H-6a, H-6b), 1.10 (1H, m, H-7a), 1.38 (1H, m,
H-7b), 3.30 (1H, m, H-9β), 1.59 (1H, m, H-10α), 1.97 (1H,
dddd, J 3.2, 5.0, 14.1, 14.2, H-10β), 1.10 (1H, m, H-11a), 1.70
(1H, m, H-11b), 0.97 (1H, m, H-12a), 1.58 (1H, d, J 12.8,
H-12′), 0.84 (3H, s, H3-13α), 1.01 (3H, s, H3-14β), 0.95 (3H, s,
H3-15), 3.42 (2H, m, H2-1′), 1.53 (2H, m, H2-2′), 1.28–1.33
(4H, H2-3′, H2-4′), 0.89 (3 H, t, J 7.0) δC (100 MHz, CDCl3)
14.1 (q, C-5′), 20.6 (t, C-6), 22.6 (t, C-4′), 25.4 (q, C-13), 26.1
(t, C-10), 26.7 (t, C-11), 28.4 (q, C-15), 28.4 (t, C-3′), 29.9 (t,
C-2′), 31.3 (q, C-14β), 33.2 (t, C-7), 34.7 (s, C-8), 36.5 (t,
C-12), 37.0 (s, C-4), 44.3 (s, C-1), 44.7 (t, C-3), 50.55 (d, C-5),
70.6 (t, C-1′), 75.2 (d, C-9), 88.3 (d, C-2); HMBC (selected cor-
relations) C-2 → H-3α, H-3β, H-12a, H-12b, H2-1′; C-1′ →
H-2α, H2-2′; C-4′ → H2-2′, H3-5′; C-5′ → H2-4′; EIMS m/z
308 (M+, 14%), 293 (M+ − 15, 10), 252 (8), 234 (18), 220 (22),
203 (74), 187 (32), 155 (100), 135 (40), 121 (48), 95 (50),
85 (80); HREIMS m/z 308.2662 [M]+ (calcd for C20H36O2,
308.4986).
Fungal cultures
P. palustris was isolated from a propolis sample collected in
Minas Gerais State (Brazil) and kept in water–glycerol 80% at
−40 °C. This strain is on deposit at the Biotechnology and
Bioassay Laboratory at the Universidade Federal de Minas
Gerais (Brazil).
The P. minioluteum culture employed in this work was iso-
lated from Serra do Cipó soil (Minas Gerais, Brazil) and kept in
water–glycerol 80% at −40 °C. This strain is on deposit at the
Biotechnology and Bioassay Laboratory of the Universidade
Federal de Minas Gerais (Brazil).
General culture conditions
P. palustris was grown on a medium composed of malt extract
30 g L−1 dissolved in water. P. minioluteum was grown on a
medium composed of glucose (10 g L−1), peptone (2.5 g L−1),
NaCl (2.5 g L−1), K2HPO4 (0.5 g L
−1) and MgSO4·7H2O
(0.25 g L−1). Surface cultures were grown in Roux bottles con-
taining 150 mL of the liquid medium. Cultures were stirred in
500 mL conical flasks containing 250 mL of liquid medium.
The substrate dissolved in ethanol was added to each flask and
the fermentation continued for an additional period of time (see
below). The mycelium was filtered and washed with EtOAc. The
broth was saturated with sodium chloride and extracted with
EtOAc. The extracts were dried over sodium sulfate, the solvent
was evaporated and the residues chromatographed on silica gel
in a gradient mixture of petroleum ether and EtOAc of increasing
polarity. In every biotransformation, a control containing the sub-
strate and the culture medium, without the presence of the
micro-organism, was run in parallel to assess substrate stability
in the culture medium. Moreover, a negative control containing
only the culture medium and the fungus was prepared to assess
micro-organism secondary metabolite production to make
certain that the isolated compounds were biotransformation pro-
ducts and not natural metabolites.
Biotransformation of (1S,2S,5S,8R,9R)-2-methoxyclovan-9-ol
(1) by P. palustris. Compound 1 (120 mg) was distributed
between 8 Roux bottles containing a 4-day culture of P. palustris
and grown for a further 10 days. Column chromatography, fol-
lowed by semi-preparative HPLC purification, yielded 3 (3.4 mg,
3%) and 4 (11.0 mg, 10%), 2 (2.3 mg, 2%), 5 (1.1 mg, 1%), and
6 (4.8 mg, 4%).
(1R,2S,5S,8R,9S,10R)-2-Methoxyclovane-9,10-diol (5). Obtained
as a colourless oil; [α]25D +4.5 (c 0.10 in MeOH); IR: νmax/cm
−1
3420 (OH); 1H and 13C-NMR data see Table 1; HMBC (selected
correlations) C1 → H-3α; C4 → H-3α,H3-13α,H3-14β; C5 →
H-3α,H-11α,H3-13α,H3-14β; C9 → H3-15; C-10 → H-11α,
H-11β; EIMS m/z 268 [M]+ (6), 250 (3), 236 (15), 218 (8), 205
(10), 192 (14), 161 (22), 137 (50), 99 (100); HRMS m/z
268.2024 [M]+ (calcd for C16H28O3, 268.2038).
(1S,2S,5S,7R,8R,9R)-2-Methoxyclovane-7,9-diol (6). Obtained
as colourless needles; mp 77–80 °C (from EtOAc); [α]25D −11.5
(c 0.11 in, MeOH); IR: νmax/cm
−1 3410 (OH); 1H and 13C-NMR
data see Table 1; HMBC (selected correlations) C1 → H-11a,
H-11b, H-12a,H-12b; C2 → –OCH3̲,H-3α,H-3β, H-11a,H-11b
















































H-12a,H-12b; C5 → H-12a,H3-13α,H3-14β; C7 → H-6α,H-6β,
H-12a,H-12b,H3-15; C-8 → H-6α,H3-15; HRMS m/z 268.1979
[M]+ (calcd for C16H28O3, 268.2038).
Biotransformation of (1S,2S,5S,8R,9R)-2-methoxyclovan-9-ol
(1) by P. minioluteum. Compound 1 (450 mg) was distributed
between 15 Roux bottles containing a 4-day culture of P. minio-
luteum and grown for a further 10 days. Ethyl acetate extraction,
solvent removal in vacuo, followed by column chromatography
and semi-preparative HPLC purification, yielded compounds 3
(73 mg, 0.30 mmol, 17%) and 4 (48 mg, 0.20 mmol, 11%).
Biotransformation of (1S,2S,5S,8R,9R)-2-propoxyclovan-9-ol
(9) by P. minioluteum. Compound 9 (60 mg) was distributed
between 2 Roux bottles containing a 4-day culture of P. minio-
luteum and grown for a further 10 days. Ethyl acetate extraction,
solvent removal in vacuo, followed by column chromatography
and semi-preparative HPLC purification, yielded compounds 3
(4 mg, 0.017 mmol, 8%) and 4 (1 mg, 0.004 mmol, 2%) and
allowed recuperation of 7 mg of compound 9.
Biotransformations of (1S,2S,5S,8R,9R)-2-propoxyclovan-9-ol
(10) and (1S,2S,5S,8R,9R)-2-(2′-(p-nitrophenoxy)ethoxy)clovan-
9-ol (11) by P. minioluteum. Compounds 10 and 11 (60 mg each)
were independently distributed between 2 Roux bottles contain-
ing a 4-day culture of P. minioluteum and grown for a further 10
days. Ethyl acetate extraction, solvent removal in vacuo, fol-
lowed by column chromatography, permitted recovery of starting
material. No clovane derivatives were obtained.
Biotransformation of (1S,2S,5S,8R)-8,9-seco-8-hydroxy-2-
methoxyclovan-9-olactone (8) by P. minioluteum. Lactone 8
(240 mg) was distributed between 8 Roux bottles containing a 4-
day culture of P. minioluteum and grown for a further 10 days.
Ethyl acetate extraction, solvent removal in vacuo, followed by
column chromatography and semi-preparative HPLC purifi-
cation, yielded compound 2 (37 mg, 0.15 mmol, 16%).
(1S,2S,5S,8R)-Rumphellclovane A (2). Colourless oil, [α]25D
+6.2 (c 0.10, MeOH); (lit.,10 [α]23D +11 (c 0.025, CHCl3)).
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